ToxiCoLoGy serViCes SPARCL : Use of a novel technology in ...€¦ · spArCL Kit. F. Luminometer...

CiToxLAB Group CompAnies

CiToxLAB in France+33 (0)2 32 29 26 [email protected]. 563 - 27005 evreux Cedex, France

CiToxLAB in North-America+1 888 353 [email protected], Armand-Frappier Blvd,Laval, Quebec, H7V 4B3, Canada

CiToxLAB in Denmark+45 56 86 15 [email protected] 36A, ejby,DK-4623 Lille skensved, Denmark

CiToxLAB in Hungary+ 36 88 [email protected]ém, szabadságpuszta, 8200, Hungary

Atlanbio+33 (0)2 51 10 01 [email protected] rue Graham Bell - Z.i de Brais B.p 40309,44605 saint nazaire Cedex, France

ALso represenTeD By

Media Services Ltd+81 3 3666 [email protected] 16 Bldg 7F 1-11-2 nihonbashi Kayabacho,Chuo-ku, Tokyo 103-0025, Japan

Croen Research Inc.+82 31 888 [email protected] institutes of ConvergenceTechnology - B-6th Fl., 864-1, lui-dong,yeongtong-gu, suwon-si - Gyeonggi-do,443-270, Korea

pArTner CompAny

Stemina+1 608 204 [email protected] south rosa road,suite 150 madison,Wisconsin 53719, usA

ToxiCoLoGy serViCes• General toxicology:

- rodents - non-rodents: dogs, nHps and minipigs

• infusion• inhalation• Dermal• ocular• immunotoxicology• reproductive toxicology including minipigs and nHps• Carcinogenicity studies also in rasH2 and p53+/- mice• Genetic toxicology: iCH compliant package• In vitro toxicology : BCop, mussT, DprA, photo 3T3,

episkin™• Agrochemical / Chemical / reACH• QsAr • physical chemistry• ecotoxicology: wide range of test species

sAFeTy pHArmACoLoGy• integrated safety pharmacology in Toxicology studies

- CV (JeT), Bp- respiratory (JeT), plethysmography- Cns (FoB) and JeT-eeG

• safety pharmacology core battery• early safety pharmacology screening

- herG- rodent and non-rodent LVp telemetry- Anesthetized models: eCG, ABp, LVp and QA

DmpK AnD BiomArKers• radiolabelled DmpK: in all species• Bioanalysis LC-ms/ms, GC-ms/ms, LC-iCp/ms, eLisA, riA• Toxicogenomics, mirnA: Affymetrix™ Accredited service

provider, next Generation sequencing (illumina®)• immunology: 10-color flow cytometer, Luminex, mesoscale

speCiALiZeD experTise• Juvenile studies including minipigs• Fertility studies in rodents and nHps• radiation safety and efficacy studies• Tissue Cross reactivity: human and animal tissue banks• Gene therapy vector biodistribution via qpCr• es cell testing: devTox™ and cardioTox™ (with stemina) • Lead optimization and predictive toxicology services:

Leadscreen™

www.citoxlab.com

SPARCLTM: Use of a novel technology in validation of a Non-Human Primate

C-Reactive Protein assay in serum

iohann Boulay, maude Bigras, Karine Blouin, Karine Dumaresq-Doiron, renée riffon and Chris Chadwick

GLp CeRTIFIeD

www.citoxlab.com

SPARCLTM: Use of a novel technology in validation of a Non-Human Primate C-Reactive Protein assay in serum iohann Boulay 1, maude Bigras 1, Karine Blouin 1, Karine Dumaresq-Doiron 1, renée riffon 1 and Chris Chadwick 2

1. immunology Department, CiToxLAB north America, Laval, Quebec, Canada - 2. Life Diagnostics, inc.

INTRODUCTIONBiomarker assays have become more widely used over the years due to their role in drug discovery and development. C-reactive protein (Crp) is an acute-phase protein synthesized by the liver and released in response to tissue injury, infection or inflammation (1). Crp is an annular (ring-shaped), pentameric protein which level increases following interleukin-6 secretion by macrophages and T cells. its physiological role is to bind to lysophosphatidylcholine expressed on the surface of dead or dying cells (and some types of bacteria) in order to activate the complement system via the C1Q complex (2). up to now Crp has been quantified using eLisA (enzyme-Linked immunosorbent Assay), but alternative methodology is being explored to facilitate the integration of Crp analysis in toxicology studies.

MeTHODOLOGYspArCLTm (spatial proximity Analyte reagent Capture Luminescence) novel technology is a proximity-dependent, homogenous, chemiluminescent detection method that allows rapid and cost effective immunoassay development, validation and sample analysis. in a spArCL assay, a chemiluminescent substrate (acridan) is brought into the proximity of an oxidative enzyme (horseradish peroxidase: Hrp) through a specific antigen/antibody interaction. A flash of light proportional to the quantity of analyte present in the sample is generated upon addition of a trigger solution containing H2o2 and para-hydroxycinnamic acid (pHCA). There is no need to remove excess reactants, as acridan-conjugated antibodies distant from Hrp produce no signal. Furthermore, to enhance the signal to noise ratio, a background reducing agent can be added to minimize the background signal from unbound reactants (3).

Assay workflowThe monkey Crp spArCL kit produced by Life Diagnostics, inc. was selected and slightly adapted for use. - affinity-purified Crp-specific antibodies are mixed with standards, positive controls or serum samples in a 96-well white plate - background-reducing reagent is added after sample incubation - the plate is placed in a luminometer, then the trigger solution is injected into each well and luminescence is immediately measured.

ReSULTSPrecision and Ruggedness precision samples consisted of Cynomolgus monkey serum containing endogenous Crp. For uLoQ (upper Limit of Quantification) and high levels, serum from animals induced with Lps (lipopolysaccharide) was used. An intra-assay precision assessment was also performed in rhesus monkey serum.

Selectivitymonkey serum from individuals with low and high levels of endogenous Crp was spiked with an amount of Crp equivalent to the endogenous level.

Parallelismsamples from non-treated and Lps-induced individuals were tested for parallelism. Depending on the Crp levels present in the samples, serial dilutions were prepared to bring the samples into the quantification range. results at the mrD (minimum required Di lut ion) or beyond (depending on the dilution range) were used for reference in the evaluation of the % difference upon dilution.

Stabilitysamples containing high and low levels of endogenous Crp were used to assess the various stability conditions. Long-term stability is currently ongoing, but was demonstrated to be at least 70-days when stored at -70°C.

Hemolysis Hemolysis was shown to have no impact on Crp measurement.

C-reactive protein induction in NHP The assay could be successfully used to study Crp induction kinetic as it has been demonstrated that Crp significantly increases from 8h after dosing animals with Lps. The assay could also be used in the study of inflammation response to coronary (LAD) ligation, in which Crp increase was observed shortly after cardiac Troponin-i (cTni) was released (as measured using another validated spArCL cTni assay).

CONCLUSIONA novel method for the quantification of Crp in monkey serum samples, spArCLTm, was successfully validated. The spArCL assay presents an advantage of short assay run times since no washing is required. it allows high sample throughput, and the analytical range covers relevant concentrations in non-human primates.

Sample ID

Dilution factor (range)

Adjusted Result

( g/mL)

% difference (range)

Overall %CV

Sample ID


Adjusted Result

( g/mL)


Overall %CV

Sample ID


Adjusted Result

( g/mL)

% difference (range) Overall %CV

Female 1 100 - 3.200 22.30 - 25.84 -10.5 to 4.2 5.6 Male 1 50 - 1.600 7.455 - 8.867 -17.3 to -3.4 7.5 Female 1 50 - 1.600 7.845 - 8.278 0.7 to 5.4 2.3

Female 2 50 - 1.600 7.557 - 8.417 -0.3 to 10.5 4.5 Male 2 50 - 800 5.605 - 6.516 -7.6 to 7.4 6.5 Female 2 50 - 800 3.353 - 3.928 -15.8 to -1.6 6.3

Female 3 400 - 3.200 56.13 - 58.59 -2.2 to 2.1 1.8 Male 3 50 - 1.600 3.162 - 7.300 -2.8 to 76.7 39.3 Female 3(LPS induced) 4.800 - 19.200 795.2 - 833.5 1.0 to 4.7 2.5

Female 4 50 - 800 5.949 - 6.384 -3.8 to 3.2 2.7 Male 4 50 - 400 3.075 - 3.417 -10.5 to -2.3 5.2 Female 4(LPS induced) 4.800 - 19.200 772.5 - 808.9 0.5 to 4.6 2.6

Female 5 50 - 400 1.782 - 1.862 2.0 to 4.4 1.9 Male 5 50 - 800 3.658 - 4.211 -13.3 to 0.8 6.7 Male 1 50 - 800 3.580 - 3.944 -1.1 to 8.6 4.2

Female 6 50 - 1.600 9.829 - 10.835 3.3 to 9.7 3.2 Male 6 50 - 1.600 8.746 - 9.579 -9.1 to -5.0 3.2 Male 2 50 - 800 3.861 - 4.231 -3.0 to 6.2 3.4

Female 7(LPS induced) 9.000 - 243.000 1.061 - 1.097 -0.3 to 3.1 1.5 Male 7

(LPS induced) 9.000 - 81.000 722.0 - 785.7 -5.4 to 3.1 4.3 Male 3 50 - 800 3.956 - 4.130 -1.4 to 2.9 1.8

Sample ID


Adjusted Result

( g/mL)


Overall %CV

Sample ID


Adjusted Result

( g/mL)


Overall %CV

Sample ID


Adjusted Result

( g/mL)

% difference (range) Overall %CV

Female 1 100 - 3.200 22.30 - 25.84 -10.5 to 4.2 5.6 Male 1 50 - 1.600 7.455 - 8.867 -17.3 to -3.4 7.5 Female 1 50 - 1.600 7.845 - 8.278 0.7 to 5.4 2.3

Female 2 50 - 1.600 7.557 - 8.417 -0.3 to 10.5 4.5 Male 2 50 - 800 5.605 - 6.516 -7.6 to 7.4 6.5 Female 2 50 - 800 3.353 - 3.928 -15.8 to -1.6 6.3

Female 3 400 - 3.200 56.13 - 58.59 -2.2 to 2.1 1.8 Male 3 50 - 1.600 3.162 - 7.300 -2.8 to 76.7 39.3 Female 3(LPS induced) 4.800 - 19.200 795.2 - 833.5 1.0 to 4.7 2.5

Female 4 50 - 800 5.949 - 6.384 -3.8 to 3.2 2.7 Male 4 50 - 400 3.075 - 3.417 -10.5 to -2.3 5.2 Female 4(LPS induced) 4.800 - 19.200 772.5 - 808.9 0.5 to 4.6 2.6

Female 5 50 - 400 1.782 - 1.862 2.0 to 4.4 1.9 Male 5 50 - 800 3.658 - 4.211 -13.3 to 0.8 6.7 Male 1 50 - 800 3.580 - 3.944 -1.1 to 8.6 4.2

Female 6 50 - 1.600 9.829 - 10.835 3.3 to 9.7 3.2 Male 6 50 - 1.600 8.746 - 9.579 -9.1 to -5.0 3.2 Male 2 50 - 800 3.861 - 4.231 -3.0 to 6.2 3.4

Female 7(LPS induced) 9.000 - 243.000 1.061 - 1.097 -0.3 to 3.1 1.5 Male 7

(LPS induced) 9.000 - 81.000 722.0 - 785.7 -5.4 to 3.1 4.3 Male 3 50 - 800 3.956 - 4.130 -1.4 to 2.9 1.8

Figure 2. spArCL key components. A. Hrp labeled Antibody. B. immunoassay target (analyte). C. 96 well low binding white plate. D. Acridan labeled Antibody. e. spArCL Kit. F. Luminometer

Figure 1. pentameric C-reactive protein

Figure 7. Crp concentration in Cynomolgus sera before and after Lps treatment

Table 4. parallelism in various Cynomolgus monkeys

Table 5. parallelism in various rhesus monkeys

Figure 3. A representative spArCL assay. specific antibody and antigen interaction brings acridan and Hrp into close proximity, the addition trigger solution then causes a flash of light

Figure 8. cTnl and Crp concentrations in Cynomolgus and rhesus (n=2 each) monkey sera before and after coronary ligation

Mean(range; ng/mL)

%CV(range)

Overall Mean (ng/mL)

Overall %CV

Mean analyst A (ng/mL)

Mean analyst B (ng/mL)

Mean(ng/mL) %CV

246.1 254.6%difference -3.4160.6 184.0

%difference -13.750.08 50.63

%difference -1.112.55 13.56

%difference -7.74.053 4.694

%difference -14.7

50.34

2.0 - 7.2 13.03 9.5

46.22 - 54.47

LLOQ 3.520 - 5.127

ULOQ 1.3 - 21.8 249.3

3.1 - 13.6 171.7144.8 - 187.1

222.5 - 367.5

Medium

Low

High

1.3 - 7.0 4.357

12.05 - 15.31

1.1 - 5.7

Sample ID

RuggednessIntra-assay precision Inter-assay precision

12.6

15.1

13.3

Low

Sample ID

ULOQ

High

7.1

297.8 8.4

211.6 6.0

Intra-assay precision

53.08 4.4

14.98 2.0

LLOQ 3.934 1.8

Medium

Unspiked Measured Spiked Expected Spiked

MeasuredUnspiked Measured Spiked Expected Spiked

Measured

Female 1- High 78.55 75.00 153.55 183.89 19.8 Female 1- Low 18.41 12.00 30.41 29.91 -1.6Female 2 - High 41.61 35.00 76.61 83.22 8.6 Female 2 - Low 13.94 12.00 25.94 28.85 11.2Female 3 - High 115.86 95.00 210.86 268.33* NA Female 3 - Low 14.20 12.00 26.20 28.42 8.5Male 1 - High 71.64 75.00 146.64 169.28 15.4 Male 1 - Low 19.59 12.00 31.59 33.74 6.8Male 2 - High 96.58 75.00 171.58 211.68 23.4 Male 2 - Low 15.49 12.00 27.49 28.94 5.3Male 3 - High 106.28 95.00 201.28 387.10* NA Male 3 - Low 13.27 12.00 25.27 25.90 2.5

Sample ID %RE

CRP Concentration (ng/mL)Sample

ID

CRP Concentration (ng/mL)%RE

Table 1. intra- and inter-Assay precision results and ruggedness (inter-analyst precision) in Cynomolgus monkey sera

Table 3. selectivity in various Cynomolgus monkeys

Table 2. intra-Assay precision results in rhesus monkey sera

Conditions

Sample ID Low High Low High Low High

Reference concentration (ng/mL) 13.03 171.68 13.03 171.68 13.03 171.68

Mean 13.38 168.89 12.77 150.26 12.95 150.23%CV 1.5 8.1 2.3 7.6 2.2 3.3%RE 2.7 -1.6 -2.0 -12.5 -0.6 -12.5

n 3 3 4 4 4 4

Long-term stability (70 days) at -70°CBench-top for 18h 3 Freeze-thaw cycles

Sample ID

Adjusted Result

( g/mL)

Hemolyzed sample Adjusted Result

( g/mL)% RE

Male 1 5.254 4.558 -13.2

Male 2 4.073 3.797 -6.8

Female 1 2.966 2.814 -5.1

Table 6. monkey Crp assay: stability results

Table 7. impact of hemolysis in various monkey individuals

Figure 5. Crp concentration in Cynomolgus monkey individual sera upon dilution (between 50- to 243 000-fold)

Figure 6. Crp concentration in rhesus monkey individual sera upon dilution (between 50- to 19 200-fold)

T20

31

Mean(range; ng/mL)

%CV(range)

Overall Mean (ng/mL)

Overall %CV

Mean analyst A (ng/mL)

Mean analyst B (ng/mL)

Mean(ng/mL) %CV

246.1 254.6%difference -3.4160.6 184.0

%difference -13.750.08 50.63

%difference -1.112.55 13.56

%difference -7.74.053 4.694

%difference -14.7

50.34

2.0 - 7.2 13.03 9.5

46.22 - 54.47

LLOQ 3.520 - 5.127

ULOQ 1.3 - 21.8 249.3

3.1 - 13.6 171.7144.8 - 187.1

222.5 - 367.5

Medium

Low

High

1.3 - 7.0 4.357

12.05 - 15.31

1.1 - 5.7

Sample ID

RuggednessIntra-assay precision Inter-assay precision

12.6

15.1

13.3

Low

Sample ID

ULOQ

High

7.1

297.8 8.4

211.6 6.0

Intra-assay precision

53.08 4.4

14.98 2.0

LLOQ 3.934 1.8

Medium

ReFeReNCeS 1. Du Clos T. W. Annals of medicine, 2000, 32(4): 274-8 - 2. Thompson D. et al. structure. 1999; 7(2): 169-177 - 3. Text and Figures 1 and 2 courtesy of Beckman Coulter inc. - 4. Guidance for industry: Bioanalytical method Validation (2001), CDer and CVm. - 5. Jean W. Lee et al. pharm res. 2005; 23: 312-328 - 6. Valentin m.-A. et al., J. pharm. Biomed. Anal. 2011; 55: 869-77. spArCL is a trademark of Lumigen, inc. and Beckman Coulter, inc.

Figure 4. example of a spArCLTm flash luminescence signal for the highest Crp standard. Luminescence was measured every 0.02 seconds for 1 second.

*result above quantification range, % relative error cannot be determined

ToxiCoLoGy serViCes SPARCL : Use of a novel technology in ...€¦ · spArCL Kit. F. Luminometer...

Documents

Transcript of ToxiCoLoGy serViCes SPARCL : Use of a novel technology in ...€¦ · spArCL Kit. F. Luminometer...